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ACTH lowers serum lipids in steroid-treated hyperlipemic
patients with kidney disease
ANNA-LENA BERG and PETER NILSSON-EHLE
Departments of Nephrology and Clinical Chemistiy, University Hospital, Lund, Sweden
ACTH lowers serum lipids in steroid-treated hyperlipemic patients
with kidney disease. The mechanisms behind secondaiy hyperlipidemia in
patients with various chronic inflammatory diseases are not known in
detail. We have recently demonstrated that ACTH exerts strong hypolipi-
demic effects in healthy volunteers. To test the clinical relevance of this
finding, we administrated ACTH during three weeks to nine hyperlipid-
ernie steroid-treated patients with kidney disease. Before administration
of ACTH 1-24, plasma ACTH concentrations were low. Treatment with
ACTH led to 20 to 50% reductions in serum concentrations of triglycer-
ides, cholesterol, LDL cholesterol and Apo B as well as of Lp(a). HDL
cholesterol and Apo Al concentrations increased by 10 to 25%. HL
activity in postheparin plasma decreased by about 40% and LPL activity,
which was initially low, increased by about 140%. The effects of ACTH
were similar in kidney transplant recipients and in patients with inflam-
matory kidney disease. Our results indicate that hyperlipidemia in steroid
treated patients with kidney disease may at least partly be due to
iatrogenic ACTH deficiency.
Patients on steroid treatment for various chronic inflammatory
diseases frequently develop hyperlipidemia with increased levels
of cholesterol and triglycerides in serum [1] The mechanisms
behind such secondary hyperlipidemias are not known in detail,
but it is generally assumed that the underlying disease and/or
ensuing organ damage may play a pathogenetic role.
We have recently demonstrated that ACTH exerts strong
hypolipidemic effects in humans [2, 31. ACTH administration to
healthy volunteers resulted in rapid reductions of Apo B and the
Apo B containing lipoproteins LDL and VLDL, while HDL
concentrations increased significantly [3]. Studies in Hep G2 cells
indicated that the lipid-lowering effects were due to a direct action
of ACTH and were mediated through an up-regulation of LDL
receptor activity [3] and a down-regulation of hepatic lipase
activity (A.L. Berg, P. Nilsson-Ehle, manuscript to be published).
This raised the possibility that the hyperlipidemia in steroid
treated patients might be due to iatrogenic ACTH deficiency,
induced by feedback inhibition of ACTH production by glucocor-
ticoid medication.
To test this possibility, we administrated ACTH to nine steroid-
treated patients with kidney disease and followed their serum
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lipoprotein concentrations and activities of hepatic lipase and
lipoprotein lipase in postheparin plasma.
Methods
Patients and blood sampling
Nine nondiabetic steroid-treated male patients with kidney
disease (aged 27 to 51 years, mean 40 years) were included in the
study. They were all out-patients and were working throughout
the study. Their medical histories, physical examinations and a set
of routine laboratory tests did not reveal any signs of liver or
endocrine disease. The patients selected were not obese and did
not have heavy alcohol habits. Familial hyperlipidemia was not
known among the patients, and none was nephrotic as a result of
the underlying kidney disease. Thus the hyperlipidemia was most
likely secondary to kidney disease. They all had stable renal
function with serum creatinine (Sr) below 150 j.mol/liter and
moderate hyperlipidemia (serum cholesterol above 6.0 mmol/liter
and/or a fasting level of serum triglycerides above 2.0 mmol/liter).
Five patients had a renal transplant (2 cases due to polycystic
kidney disease, and the others to vesico-urethral reflux, congenital
malformation of the kidneys and poststreptococcal glomerulone-
phritis, respectively). Of the remaining four patients two had
Wegeners granulomatosis, one had IgA-nephritis and one had
systemic lupus erythematosus.
All medications were kept unchanged during the experimental
period of 30 days. All patients were treated with synthetic
glucocorticoid (Prednisolon, Kabi Pharmacia AB, Uppsala, Swe-
den) in doses ranging from 7.5 mg to 10 mg daily since at least six
months. Eight patients were also treated with azathioprin (Imurel;
The Wellcome Foundation Ltd, London, UK) 100 mg to 200 mg
daily, and one patient with Wegeners granulomatosis was treated
with 100 mg cyclophosphamide (Sendoxane, ASTA Medica AG,
Frankfurt, Germany) daily. Three of the patients with kidney
transplants were treated with cyclosporine (Sandimmun, Sandoz
Pharma Ltd, Basle, Switzerland) 200 to 250 mg daily.
ACTH was given as the biologically active N-terminal 24-
peptide, ACTH 1-24, in a slow-release preparation (Synacthen
Depot; CIBA-Geigy AG, Baste, Switzerland). The drug was
administered by intramuscular injection of one mg, at 8 to 9 a.m.,
on days 0, 7, 9, 11, 14, 15, 16 and 17.
On days 0, 7, 14, 18 and 30, blood samples were obtained for
various biochemical measurements. On days 0, 7 and 14 the
samples were obtained immediately before the ACTH injection.
The samples were drawn at 7 to 9 a.m., with the subjects fasting
since 10 p.m. the previous night. On days 0, 7, 14, 18 and 30,
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Table 1. Concentrations of hemoglobin, creatinine, albumin, a1-antitiypsin, orosomucoid, C-reactive protein (CRP), protein HC (HC) and
immunoglobulins in blood (B), serum (S), plasma (P) or urine (U) after administration of 1 mg ACTH 1-24 on days 0, 7, 9, 11, 14, 15, 16 and 17 to
nine patients
Day 0 Day 18 Day 30
B hemoglobin glliter 139 (127—154) 137 (128—149) 142 (122—158)
Scr pmol/liter 125 (96—145) 120 (88—140) 119 (86—144)
Ab glliter 34 (31—40) 33 (27—35) 32 (26—39)
P a1-antitrypsin glliter 1.47 (0.80—2.07) 1.43 (0.81—1.93) 1.48 (0.81—2.05)
P orosomucoid g/liter 1.05 (0.69—1.52) 1.05 (0.66—1.48) 1.06 (0.64—1.44)
P CRP mg/liter <5 (<5—11) <5 ( ) <5 (<5—19)
IgG g/liter 9.9 (8—14.1) 9.3 (7.8—14.1) 9.5 (8.1—14.3)
P1g/liter 2.3 (1.1—3.7) 2.3 (1.1—3.6) 2.3 (1.1—3.6)
1JgM glliter 1.3 (0.4—7.2) 1.3 (0.5—7.0) 1.4 (0.3—7.0)
UAIh mg/liter 34 (7—1300) 44 (7—1390) 40(6—1370)
Uig mg/L 5 (5—28) 6 (5—39) 5 (5—37)
UHC mg/liter 13 (5—26) 14 (5—28) 12(5—20)
Data are given as median (range).
Reference ranges are: B-Hb 131—163 g/liter, Sr 55—116 j.mol/liter, Ajh 36—48 g/liter, P a1-antitrypsin 0.90—1.70 glliter, P orosomucoid 0.55—1.05
g/liter, P CRP <5 mg/liter, IgG 7.0—15.0 g/liter, 1gA 0.5—3.0 g/liter, p1gM 0.4—2.0 g/liter, UAIb <25 mg/liter, U1g0 <5 mg/liter, UHC <10 mg/liter.
Table 2. P-ACTH, S-cortisol and dU-Cortisol before, during and after ACTH 1-24 administration to 9 glucocorticoida treated patients
Day 0 Day 7 Day 14 Day 18 Day 30
P ACTHpmol/liter 2(<2—11) 2 (<2—9.4) 2(<2—4.6) <2 ( ) 2.8 (<2—8.8)
S cortisol nmol/liter 144 (136—534) 338 (154—564) 374 (195—609)' 1579 (437—2000)" 300 (146—449)
dU cortisol nmol/day 95 (75—494) 233 (90—652)" 574 (94_1100)c 4800 (1940_7800)c 241 (21—454)
One mg of ACTH l24t was administrated on days 0, 7, 9, 11, 14, 15, 16 and 17. Data are given as median (range). Reference ranges are: P ACTH
2—10 pmol/liter, S cortisol 200—800 nmol/liter, dU cortisol 80—350 nmol/day.
"Not measured by cortisol assay
h Not measured by ACTH assay
P < 0.01 compared to day 0
24-hour urine portions were collected for determination of corti-
sol excretion.
Measurements included serum cholesterol, serum triglycerides,
HDL cholesterol, Apo B, Apo Al, Lp(a), Sr, blood hemoglobin
(B-Hb), plasma ACTH, serum cortisol, urinary cortisol, and
quantification of proteins in plasma and urine.
For the determination of lipoprotein lipase (LPL) and hepatic
lipase (HL) activities, postheparin plasma was obtained 15 min-
utes after the intravenous injection of 50 U heparin per kg body wt
[4].
Plasma and serum was separated by centrifugation, and all
samples were frozen at —20°C to allow analysis in the same series.
Informed consent was obtained from each patient and the study
was approved by the Ethics Committee of Lund University.
Cholesterol and triglyceride concentrations were determined
enzymatically using kits from Boehringer-Mannheim. Before de-
termination of HDL cholesterol, other lipoproteins were precip-
itated with dextran sulphate and MgCl2 [5]. Low density lipopro-
tein (LDL) cholesterol concentrations were calculated by the
Friedewald formula [6], modified for use with SI units. Serum
concentrations of apolipoproteins B and Al and lipoprotein(a)
were measured using immunoradiometric kits from Pharmacia,
Uppsala, Sweden.
LPL and HL activities were measured using radioactively
labeled triglyceride emulsions stabilized by phospholipid as sub-
strate [4].
ACTH in plasma was measured by an immunoradiometric assay
from Eurodiagnostics BV (MILAB, Malmö, Sweden). This is a
double-antibody assay, specific for native ACTH, but the synthetic
ACTH 1-24, when present in abundance, may cause falsely low
values by consuming one of the antibodies necessary for detection
of ACTH. Cortisol in serum and urine was assayed by a radioim-
munoassay kit (Farmos Diagnostica, Turku, Finland). This
method is specific for cortisol, and prednisolone does not interfere
with the assay.
B-Hb was estimated by the in cyanmethemoglobin method in a
Sysmex-NE 8000; 5Cr was estimated with the Kodak Ektachem
system, and proteins in serum and urine were measured by
immunoturbidimetry.
Statistical differences were evaluated by Wilcoxon's rank order
test for the paired case.
Results
5Cr levels and the protein patterns in plasma and urine were
unchanged during the experimental period (Table 1), indicating
that the clinical condition and renal function of the patients were
stable during the study.
The regimen was well tolerated by most of the participants. Two
patients reported mild symptoms of increased psychological ac-
tivity such as increased alertness or irritability; one of these
discontinued the study on day 17. From three patients we did not
obtain blood samples on day 30. One patient reported signs of
fluid retention, but the concentrations of B-Hb and immuno-
globulins in plasma were constant in all subjects, demonstrating
that alterations in fluid balance did not contribute to the observed
changes in serum lipoprotein concentrations (Table 1). Blood
glucose, recorded on each sampling occasion, was not affected.
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Fig. 1. Effects of administration 0fACTH 1.24 on serum lipids and lipoproteins in nine patients with kidney disease. ACTH (1 mg) was given as indicated
by arrows on day 0, 7, 9, 11, 14, 15, 16, and 17. Data are given as mean relative changes. Filled symbols indicate kidney transplant recipients and open
symbols patients with inflammatory kidney disease. (A) Serum cholesterol (S-chol) and serum triglycerides (S-TG). (B) Serum low density lipoprotein
cholesterol (LDL-chol) and high density lipoprotein cholesterol (HDL-chol). (C) Apolipoprotein concentrations (Apo Al and Apo B). (D) lipoprotein
(a), (E) Lipoprotein lipase (LPL) and hepatic lipase (HL) activities.
Blood pressures were stable, and none of the patients reported
changes in appetite or dietary habits.
Before administration of ACTH 1-24, plasma ACTH concen-
trations were at the lower reference limit, while serum cortisol
concentrations were below and urinary cortisol excretion in the
lower part of the reference range (Table 2). After administration
of ACTH 1-24, serum cortisol concentrations and urinary cortisol
excretion increased markedly (Table 2). The plasma ACTH
concentrations recorded were extremely low. Taking into consid-
eration the methodological procedures described earlier, these
results demonstrate that the treatment had induced marked
hyperfunction of the pituitary—adrenal axis.
Treatment with ACTH 1-24 led to marked reductions in serum
concentrations of triglycerides, cholesterol, LDL cholesterol and
Apo B. The values, which all represent components of Apo
B-containing lipoproteins, were 20 to 50% lower than the initial
values (P < 0.01, Fig. 1 A-C, Table 3). These effects were most
pronounced on day 14 and 18, but were already evident on day 7.
The decrease was more pronounced in subjects with high initial
lipid and lipoprotein concentrations (Fig. 2). On day 30, two
weeks after the last ACTH injection, the lipoprotein concentra-
tions recovered essentially to the initial levels.
Lp(a) levels (Fig. 1D, Table 3) fell significantly on day 7 and 14
and reached levels about 40% below the initial on day 18 (P <
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Table 3. Serum (S) lipid, lipoprotein and apolipoprotein concentrations, and lipoprotein lipase (LPL) and hepatic lipase (HL) activities after
administration of 1 mg ACTH 1-24 on days 0, 7, 9, 11, 14, 15, 16 and 17 to 9 patients with kidney disease
Day 0 Day 7 Day 14 Day 18 Day 30
S cholesterol mmol/liter 7.2 (4.7—7.7) 6.8 (4_7.8)a 6.2 (4_74)a 5.55 (3.8—6.7) 6.3 (4.5—7.1)
S triglycerides mmol/liter 2.3 (1.3—4.9) 1.4 (1_3.7)a 1.3 (0.8_3.3)a 1.05 (0.7—1.3) 2.2 (1.2—4.8)
LDL cholesterol mmol/liter 5.0 (3.2—6.6) 4.9 (2.6_6.1) 4.1 (2.4_5.4)a 3.65 (2.2_5.2)a 4.2 (3.1—5.1)
HDL cholesterol mmol/liter 1.12 (0.71—1.52) 1.21 (0.84_1.69)a 1.25 (0.95_1.71)a 1.39 (1_i .75 ) 1.1 (0.92—1.51)
SA0 B gluIer 1.56 (1.13—2.11) 1.48 (1.01_1.83)a 1.22 (1_1.60)a 1.07 (0.92_1.50)a 1.24 (1—2.24)
SAtO Al glliter
S hpoprotein (a) mg/liter
1.28 (1.05—1.34)
139 (12—550)
1.34 (1.11_1.45)a
110 (8469)a
1.36 (1.2_1.53)a
88 (6—466)
1.42 (1.27_L59)a
77 (6.321)a
1.31 (1—1.39)
94(31—547)
LPL activity mU/mi 35 (19—47) 42 (20_52)a 49 (2084)a 64 (38_127)a 36 (25—57)
HL activity mU/mi 270 (139—394) 245 (99—346y 236 (96_283)a 213 (70_240)a 237 (142—341)
Data given as median (range).
a P < 0.01 compared to day 0
Reference ranges are: S cholesterol 3.5—6.0 mmol/liter, S triglycerides 0.5—1.4 mmol/liter, LDL cholesterol 2.2—4.1 mmol/liter, HDL cholesterol
0.70—1.60 mmol/liter, 5Apo B 0.40—1.30 glliter , Sr,0 Al 0.95—2.05 g/liter, S Lp(a) <700 U/liter, LPL activity 110—220 mU/ml, HL activity 320—620
mU/mi.
0.01). Again, the fall in Lp(a) was most pronounced in subjects
with high initial levels. On day 30, Lp(a) concentrations had
returned essentially to the initial level.
Apo Al concentrations increased significantly on days 7, 14 and
18, to levels 14% above the baseline (P < 0.01). HDL cholesterol
increased by about 20% (Fig. 1 B, C and Table 3). On day 30, the
concentration had returned to the initial levels.
LPL activities before ACTH administration were low, as ex-
pected in patient with kidney disease [71. LPLactivity increased by
about 140% (P < 0.01). On day 18, HL activity in postheparin
plasma was decreased by about 40% (P < 0.01; Fig. 1E and Table
3). The enzyme activities returned close to the initial levels on day
30.
The effects of ACTH on lipid metabolism were similar in all
subgroups of patients. For example, kidney transplant recipients
showed a similar development of lipid and lipoprotein concentra-
tions during the study as seen in the others (Fig. 1).
Discussion
It is well known that the pituitary—adrenal axis is important for
the regulation of lipid metabolism, but it has generally been
assumed that the effects are mediated by peripheral hormones,
that is, gonadal hormones and corticosteroids. During the last
years it has been found that growth hormone [8, 9] as well as
ACTH [2, 31 have a direct influence on lipid metabolism. In this
study we intended to investigate the clinical relevance of these
findings as relates to ACTH.
A variety of clinical disorders including immunologic, hepatic
and renal dysfunction are associated with secondary hyperlipopro-
teinemias [1]. The mechanisms behind these hyperlipidemias are
ci)
0
E
E
0
a)
U)
a)
0
'C0
-J0I
th
1.9
1.7
1.5
1.3
1.1
0.9
0.7
0.5
0
E
E
0
1)
U)
a)0
'C
C)
-J0
-J
o5
0S
S
Cl,
I—
Cl)
7
6
5
4
3
2
1
5
4
3
2
0
0 7 14 18 30
Day
0 7 14 18 30
Day
600
500
400
300
c. 200
-J
th 100
00 7 14 18 30
Day
0 7 14 18 30
Day
Fig. 2. Serum lipid and lipoprotein after
administration of 1 mg ACTH 1-24 was given to
patients on days 0, 7, 9, 11, 14, 15, 16, and 17 to
9 patients with kidney disease. Patients number 1
(0), 2 (fl), 6 (X), 7 (+) and 8 (•) had kidney
transplants and numbers 3 (s), 4 (), 5 (•)
and 9 (A) patients were diagnosed with
inflammatory kidney disease.
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not known in detail. Corticosteroids, which are frequently used to
treat such patients, may induce increased VLDL and LDL
cholesterol concentrations, and may thus contribute to such
secondary hyperlipemias.
We have earlier reported that ACTH and glucocorticoid ad-
ministration to healthy volunteers affect lipoprotein metabolism
differently. Administration of ACTH results in rapid reductions of
Apo B and the Apo B-containing lipoproteins LDL and VLDL
while glucocorticoid treatment does not [2, 3]. HDL concentra-
tions increased on both ACTH and glucocorticoid treatment,
whereas Apo Al concentrations increased only on glucocorticoid
treatment [3]. ACTH but not glucocorticoid was also associated
with marked alterations in the HDL fraction, most notably a rise
in the concentrations of HDL2, which could probably be ascribed
to a significant reduction of HL activity [3]. Neither ACTH nor
glucocorticoid administration was associated with any consistent
changes of LPL activity in healthy volunteers [31.
This study addresses the possible clinical implications of these
findings. Patients on long-term steroid treatment, with moderate
hyperlipidemia, were a logical study group, since such treatment
may reduce the endogenous ACTH levels through feedback
inhibition mechanisms. We chose to study patients with kidney
disease since lipids seem to be involved in many aspects of the
pathogenesis of progressive glomerular injury [7, 10—12]. Also,
kidney transplant recipients have a high prevalence of risk factors
for the development of atherosclerosis, including hyperlipopro-
teinemia [13—15].
As could be expected the steroid-treated patients in our study
had low ACTH concentrations in plasma. During the study ACTH
activity increased markedly, as evidenced by increasing cortisol
levels. The levels of exogenous glucocorticoids in serum were not
measured by the cortisol method, but the corticosteroid medica-
tion was constant and glucocorticoid activity high and increasing
throughout the experiment. Extrapolation from earlier studies in
healthy subjects [3] strongly suggest that the observed effects are
largely due to ACTH as such.
The present investigation demonstrates that ACTH administra-
tion strongly influences lipoprotein metabolism also in steroid
treated patients with kidney disease. ACTH administration for 18
days (in total 8 mg of Synacthen) led to marked reductions in
serum concentrations of triglycerides, cholesterol, LDL choles-
terol, Apo B, and Lp(a) by 20 to 50%, while HDL cholesterol and
Apo Al increased by 10 to 25%. The effects were already evident
after 1 mg ACTH and one week. In some respects the effects of
ACTH on lipid metabolism were more pronounced in the patients
than in healthy volunteers. For example, ACTH administration
resulted in a consistent and more marked increase of LPL activity,
in parallel with a more marked decrease of serum triglycerides in
our patients, who had initially moderate hypertriglyceridemia and
lowered LPL activities. The effects of ACTH on lipid metabolism
were similar in kidney transplant recipients and in patients with
inflammatory kidney disease.
Our results suggest that hyperlipidemia in steroid treated
patients with kidney disease may at least partly be due to
iatrogenic ACTH deficiency. The strong beneficial effects of
short-term treatment with ACTH also suggest new therapeutic
approaches. Long-term studies on the feasibility of ACTH and
ACTH derivatives in various secondary hyperlipidemias are pres-
ently underway.
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